Vertex Pharmaceuticals (VRTX) Free Cash Flow (2009 - 2026)

Vertex Pharmaceuticals' Free Cash Flow history runs 18 years deep, the most recent figure standing at $1.3 billion for Q1 2026.

• In Q1 2026, Free Cash Flow rose 66.37% year-over-year to $1.3 billion; the TTM figure through Mar 2026 stood at $3.7 billion (up 396.75% YoY), while the FY2025 annual figure was $3.2 billion, up 504.13% from the prior year.
• Free Cash Flow was $1.3 billion for Q1 2026 at Vertex Pharmaceuticals, up from $348.6 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of $1.3 billion in Q3 2024 to a low of -$3.8 billion in Q2 2024.
• Historically, Free Cash Flow has averaged $644.7 million across 5 years, with a median of $927.4 million in 2025.
• The sharpest annual moves came in 2022 and 2024: Free Cash Flow jumped 535.3% in 2022, then plunged 455.66% in 2024.
• A 5-year view of Free Cash Flow shows it stood at $1.0 billion in 2022, then sank by 83.11% to $176.5 million in 2023, then surged by 178.75% to $492.0 million in 2024, then fell by 29.15% to $348.6 million in 2025, then soared by 271.4% to $1.3 billion in 2026.
• The last three Free Cash Flow figures came in at $1.3 billion (Q1 2026), $348.6 million (Q4 2025), and $1.1 billion (Q3 2025), per Business Quant data.